ImmuCell (NASDAQ:ICCC – Get Free Report) will release its earnings data after the market closes on Wednesday, November 13th. Persons interested in participating in the company’s earnings conference call can do so using this link.
ImmuCell (NASDAQ:ICCC – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. The company had revenue of $5.47 million during the quarter. ImmuCell had a negative return on equity of 16.35% and a negative net margin of 17.44%.
ImmuCell Price Performance
ICCC opened at $3.53 on Tuesday. The stock has a 50-day moving average price of $3.65 and a 200-day moving average price of $4.10. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.37 and a quick ratio of 0.77. The firm has a market cap of $27.64 million, a PE ratio of -6.66 and a beta of 0.56. ImmuCell has a 1 year low of $3.34 and a 1 year high of $5.59.
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Stories
- Five stocks we like better than ImmuCell
- Pros And Cons Of Monthly Dividend Stocks
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Consumer Discretionary Stocks Explained
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.
